

Additional file 3 Mirogabalin daily dose for 12 weeks by renal function at enrollment (mITT population, N = 63)

Mirogabalin dose	CrCL ≥ 60 mL/min					CrCL 30 to < 60 mL/min				
	Baseline	Day 1	Week 2	Week 4	Week 8	Baseline	Day 1	Week 2	Week 4	Week 8
15 mg BID	0 (0.0)	0 (0.0)	15 (34.9)	21 (50.0)	20 (47.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
10 mg BID	1 (2.3)	1 (2.3)	22 (51.2)	14 (33.3)	16 (38.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
7.5 mg BID	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7 (43.8)	9 (56.3)	9 (56.3)
5 mg BID	43 (97.7)	43 (97.7)	6 (14.0)	6 (14.3)	6 (14.3)	1 (5.3)	1 (5.3)	8 (50.0)	6 (37.5)	6 (37.5)
2.5 mg BID	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18 (94.7)	18 (94.7)	1 (6.3)	1 (6.3)	1 (6.3)
Other	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Data are n (%).

BID, twice daily; CrCL, creatinine clearance; mITT, modified intention-to-treat.